Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,428.00
Bid: 12,432.00
Ask: 12,436.00
Change: -82.00 (-0.66%)
Spread: 4.00 (0.032%)
Open: 12,556.00
High: 12,562.00
Low: 12,420.00
Prev. Close: 12,510.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Iran leader bans import of U.S., UK COVID-19 vaccines, demands sanctions end

Fri, 08th Jan 2021 09:13

(Adds Twitter removes Khamenei tweet)

By Parisa Hafezi

DUBAI, Jan 8 (Reuters) - Iran's Supreme Leader on Friday
banned the government from importing COVID-19 vaccines from the
United States and Britain, labelling the Western powers
"untrustworthy", as the infection spreads in the Middle East’s
hardest-hit country.

In a live televised speech, Ayatollah Ali Khamenei raised
the prospect of the two Western countries, long-time adversaries
of the Islamic Republic, possibly seeking to spread the
infection to other countries.

He added however that Iran could obtain vaccines "from other
reliable places". He gave no details, but China and Russia are
both allies of Iran.

"Imports of U.S. and British vaccines into the country are
forbidden ... They're completely untrustworthy. It's not
unlikely they would want to contaminate other nations," said
Khamenei, the country's highest authority.

"Given our experience with France's HIV-tainted blood
supplies, French vaccines aren't trustworthy either," Khamenei
said, referring to the country's contaminated blood scandal of
the 1980s and 1990s.

Khamenei repeated the accusations in a tweet that was
removed by Twitter along with a message saying it violated the
platform's rules against misinformation.

Iran launched human trials of its first domestic COVID-19
vaccine candidate late last month, saying it could help Iran
defeat the pandemic despite U.S. sanctions that affect its
ability to import vaccines.

Tensions between Washington and Tehran have risen since
2018, when President Donald Trump abandoned a 2015 nuclear deal
and reimposed sanctions to pressure Iran into negotiating
stricter curbs on its nuclear program, ballistic missile
development and support for regional proxy forces.

In retaliation for U.S. sanctions, which were lifted under
the nuclear deal, Tehran has gradually violated the accord. U.S.
President-elect Joe Biden, who takes office on Jan. 20, has
pledged to rejoin the agreement if Tehran also returns to full
compliance.

Khamenei said Tehran was in no rush for the United States to
re-enter the deal, but that sanctions on the Islamic Republic
must be lifted immediately.

Iran's utmost authority, Khamenei ruled out any talks over
Tehran's missile programme and Iran's involvement in the Middle
East, as demanded by the United States and some other major
powers.

"Contrary to the U.S., Iran's involvement in the region
creates stability and is aimed at preventing instability ...
Iran’s involvement in the region is definite and will continue."

Shortly before Khamenei's speech, Iran's elite Revolutionary
Guards unveiled an underground missile base at an undisclosed
Gulf location.

The West sees Iran’s missiles both as a conventional
military threat to regional stability and a possible delivery
mechanism for nuclear weapons should Tehran develop them.

But Iran, which has one of the biggest missile programmes in
the Middle East, regards the programme as an important deterrent
and retaliatory force against the United States and other
adversaries - primarily Gulf Arabs - in the region in the event
of war.
(Reporting by Parisa Hafezi; Editing by Toby Chopra, Timothy
Heritage, William Maclean and Sonya Hepinstall)

More News
17 Jun 2024 09:09

TOP NEWS: Astra's Imfinzi plus chemo approved for cancer form in US

(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "important new option" for patients.

Read more
17 Jun 2024 07:48

LONDON BRIEFING: Astra gets US drug approval; Ascential trades in line

(Alliance News) - London's FTSE 100 is called to open solidly higher on Monday, recovering some poise after a tricky week, with eyes turning to the Bank of England.

Read more
17 Jun 2024 07:23

IN BRIEF: AstraZeneca gets positive cancer test results for Calquence

AstraZeneca PLC - Cambridge, England-based pharmaceutical maker - Reports promising test results for one of its cancer therapies. The Echo phase III trial shows that Calquence, when used in combination with bendamustine and rituximab, demonstrates a clinically meaningful improvement in progression-free survival in patients with untreated mantle cell lymphoma. Compared to standard-of-care chemoimmunotherapy, the combination with Calquence, whose generic name is acalabrutinib, shows a 27% reduced risk of disease progression or death. Mantle cell lymphoma is rare and typically aggressive form of non-Hodgkin lymphoma, Astra explains.

Read more
17 Jun 2024 07:15

AstraZeneca's Imfinzi gets US approval for endometrial cancer patients

(Sharecast News) - AstraZeneca said its Imfinzi cancer treatment had been approved in the US as treatment for adult patients with primary advanced or recurrent endometrial cancer.

Read more
12 Jun 2024 20:56

AstraZeneca's Farxiga approved to treat paediatric type-2 diabetes

(Alliance News) - AstraZeneca PLC on Wednesday said its Farxiga treatment has been approved in the US to treat some diabetes sufferers.

Read more
10 Jun 2024 09:10

LONDON BROKER RATINGS: JPMorgan cuts Aviva but lifts M&G

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and on Friday:

Read more
10 Jun 2024 08:30

TOP NEWS: Astra's Tagrisso gets US priority review for lung cancer

(Alliance News) - AstraZeneca PLC on Monday celebrated a breakthrough therapy designation for its cancer drug Tagrisso, aimed at treating a form of non-small cell lung cancer.

Read more
10 Jun 2024 07:37

LONDON BRIEFING: FTSE called down amid political uncertainty in EU

(Alliance News) - Stocks in London are called to open lower on Monday, setting off the week on the backfoot, with eyes on the US Federal Reserve's latest interest rate decision.

Read more
10 Jun 2024 06:25

London pre-open: Stocks set for lower start after EU elections

(Sharecast News) - Stocks in London look primed for a lower start as investors digest the gains made by far right parties in Austria, Germany, but above all France, at the European Union elections that were held at the weekend.

Read more
5 Jun 2024 09:52

LONDON BROKER RATINGS: Berenberg raises Taylor Wimpey to 'buy'

(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and on Tuesday:

Read more
5 Jun 2024 09:27

AstraZeneca completes USD2.4 billion Fusion Pharmaceuticals purchase

(Alliance News) - AstraZeneca PLC on Wednesday said it successfully completed the acquisition of Boston, Massachusetts-based Fusion Pharmaceuticals Inc.

Read more
3 Jun 2024 08:59

AstraZeneca cancer treatment Tagrisso recommended for approval in EU

(Alliance News) - AstraZeneca PLC said that, following further positive findings in clinical trial, Tagrisso has been recommended for use in the European Union.

Read more
3 Jun 2024 07:28

AstraZeneca's lung cancer treatment recommended for approval in EU

(Sharecast News) - AstraZeneca has announced that its Tagrisso treatment for advanced lung cancer, when combined with chemotherapy, has been recommended for approval by European regulators.

Read more
2 Jun 2024 20:03

Astra's Enhertu breast cancer trial shows 'unprecedented' results

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu slows the progression of breast cancer by about five months in women whose disease worsened after endocrine therapy - even if they had very low levels of the mutant protein targeted by the drug, according to trial results announced on Sunday.

Read more
2 Jun 2024 15:58

Astra's Enhertu delays breast cancer in patients with low HER2 levels

June 2 (Reuters) - AstraZeneca and Daiichi Sankyo's Enhertu was shown in a large trial to delay the growth of hormone-sensitive breast cancer by about five months for people with low levels of HER2 protein whose cancer progressed following endocrine therapy, according to research presented on Sunday.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.